Metsera Stock Price, News & Analysis

Metsera (Nasdaq: MTSR), a clinical-stage biopharmaceutical company focused on obesity and metabolic diseases, has announced upcoming investor conference presentations. CEO Whit Bernard will present at two major healthcare conferences in September:

• Cantor Global Healthcare Conference on September 3 at 3:20-3:50 PM EDT
• Wells Fargo Healthcare Conference on September 4 at 4:30-5:05 PM EDT

Investors can access live webcasts and replays of both presentations through the Events page in the Investors & News section at investors.metsera.com.

Metsera (NASDAQ:MTSR), a clinical-stage biopharmaceutical company, reported significant progress in its Q2 2025 pipeline for obesity and metabolic disease treatments. The company highlighted positive results for two key programs: MET-097i, a monthly GLP-1 receptor agonist with Phase 3 initiation planned for late 2025, and MET-233i, a monthly amylin analog that achieved 8.4% weight loss in five weeks with a 19-day half-life.

The company maintains a strong financial position with $530.9 million in cash, providing runway into 2027. Q2 2025 saw increased R&D expenses of $60.5 million and a net loss of $68.7 million. Multiple clinical milestones are expected in late 2025, including VESPER-1 data release, 12-week monotherapy data for MET-233i, and preliminary results from their oral peptide program.

Metsera (NASDAQ: MTSR), a clinical-stage biopharmaceutical company focused on developing treatments for obesity and metabolic diseases, announced its participation in the Goldman Sachs 46th Annual Global Healthcare Conference. CEO Whit Bernard will deliver a presentation on Wednesday, June 11, 2025, from 10:00 to 10:35 AM EDT. Investors and interested parties can access both the live webcast and replay of the presentation through the Events page in the Investors & News section on Metsera's website at investors.metsera.com.

Metsera (NASDAQ: MTSR) announced positive Phase 1 trial results for MET-233i, their first-in-class ultra-long acting amylin analog. The drug demonstrated impressive efficacy with up to 8.4% mean placebo-subtracted weight loss at Day 36 and a 19-day half-life supporting monthly dosing. The trial involved 80 participants with overweight/obesity, testing doses from 0.15mg to 2.4mg. Key findings include dose-linear pharmacokinetics, sustained weight loss effects, and favorable tolerability with no safety signals. The drug shows potential for combination with Metsera's GLP-1 receptor agonist MET-097i, positioning it as a possible first monthly multi-NuSH combination therapy. Based on these results, Metsera is advancing both monotherapy and combination trials, with additional data expected in late 2025 or early 2026.

Metsera (NASDAQ: MTSR) will present new research on its obesity treatment portfolio at the 85th Scientific Sessions of the American Diabetes Association. The presentations will focus on MET-097i, their lead monthly GLP-1 receptor agonist, featuring clinical data from its Phase 1/2 trial including body weight changes and tolerability data after twelve weekly doses and a single monthly dose. The company will also present preclinical data on MET-233i, their monthly ultra-long acting amylin analog. The scientific sessions will include a total of eight presentations covering clinical trials, preclinical research, and health economics studies. The research showcases Metsera's development of next-generation approaches for treating overweight and obesity through ultra-long acting, scalable, and combinable therapies.

Metsera (NASDAQ: MTSR) reported its Q1 2025 financial results and pipeline updates. The company's cash position stands at $588.3 million, supporting operations into 2027. Key financial metrics include R&D expenses of $57.2 million and a net loss of $76.6 million. Their lead candidate, MET-097i, a monthly GLP-1 receptor agonist, is progressing through three VESPER Phase 2b trials, with VESPER-1 data expected mid-2025. The company's pipeline includes MET-233i, a monthly amylin analog in Phase 1, and oral candidates MET-097o and MET-224o. Notable weight loss results of up to 14.2% were reported for MET-097i. The company successfully completed a $316 million IPO and appointed Jon P. Stonehouse as Director and Matthew Lang as Chief Legal Officer.

Metsera (Nasdaq: MTSR), a clinical-stage biopharmaceutical company focused on developing next-generation medicines for obesity and metabolic diseases, has announced its participation in the Bank of America 2025 Global Healthcare Conference. CEO Whit Bernard will deliver a presentation on Wednesday, May 14, 2025, from 2:20 to 2:35 P.M. PDT (5:20 – 5:35 P.M. EDT). Interested parties can access a live webcast of the presentation through the Events page in the Investors & News section of Metsera's website at investors.metsera.com.

Metsera (NASDAQ: MTSR) reported its Q4 and full year 2024 financial results, highlighting significant progress in its obesity and metabolic disease pipeline. The company's lead candidate MET-097i, a monthly GLP-1 receptor agonist, demonstrated promising Phase 2a results with up to 11.3% mean placebo-subtracted weight loss after 12 weekly doses.

Financial highlights include completion of an IPO raising $316.2 million, extending runway into 2027. Year-end cash position was $352.4 million. Full-year 2024 results showed R&D expenses of $107.5 million and G&A expenses of $26.8 million, with a net loss of $209.1 million.

Key pipeline developments include:

• Multiple Phase 2b trials for MET-097i with readouts expected mid-2025
• MET-233i Phase 1 program progressing with data expected mid-2025
• Oral formulation studies for MET-224o and MET-097o advancing
• Initiation of IND-enabling studies for MET-815i

Metsera (MTSR), a clinical-stage biopharmaceutical company focused on obesity and metabolic diseases, has announced its participation in TD Cowen's 45th Annual Health Care Conference.

The company's CEO, Whit Bernard, is scheduled to deliver a presentation on Tuesday, March 4, 2025, from 1:10 to 1:40 p.m. ET. Investors and interested parties can access a live webcast of the presentation through the Events page in the Investors & News section at investors.metsera.com. The presentation recording will remain accessible for 90 days after the event.